Abstract: Methods of altering properties of tissues, by providing an effective modifying amount of zinc, which may be in the form of zinc ions. This is accomplished through the use of topical compositions containing one or more zinc-containing components such as salts and/or other zinc compounds or complexes, particularly zinc acetate. Altering properties of tissues includes increasing or decreasing fatty tissue, increasing or decreasing epidermal thickness, increasing elastin content, and preventing or treating gum regression or atrophy. Also disclosed is the provision of a contact lens coated with a zinc-containing material, to improve vision by increasing elastin content of the lens of the eye through release of zinc ions.
Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
Type:
Grant
Filed:
February 29, 2012
Date of Patent:
December 23, 2014
Assignee:
BioEnergenix, LLC
Inventors:
John M. McCall, John McKearn, Donna L. Romero, Michael Clare
Abstract: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 ?g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.
Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. Such compounds include inhibitors of cytochrome C17?-hydroxylase/C17,20-lyase such as 3-?-Hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-diene.
Type:
Grant
Filed:
August 5, 2010
Date of Patent:
July 29, 2014
Assignee:
Tokai Pharmaceuticals, Inc.
Inventors:
Jodie Pope Morrison, Cy Aaron Stein, David Scott Casebier
Abstract: Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.
Type:
Grant
Filed:
June 17, 2009
Date of Patent:
July 22, 2014
Assignee:
Takeda Pharmaceuticals U.S.A., Inc.
Inventors:
David Baron, Keisuke Hirai, Yasushi Shintani, Osamu Uchikawa
Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
July 15, 2014
Assignee:
AMGEN Inc.
Inventors:
James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Holger Monenschein, Thomas T. Nguyen, Nobuko Nishimura, Wenge Zhong
Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.
Type:
Grant
Filed:
August 30, 2012
Date of Patent:
July 8, 2014
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Stephan Bachmann, Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Bernd Kuhn, Jens-Uwe Peters, Markus Rudolph
Abstract: Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.
Type:
Grant
Filed:
March 26, 2010
Date of Patent:
July 8, 2014
Assignee:
Vivacell Biotechnology Espana, S.L.
Inventors:
Eduardo Muñoz Blanco, Giovanni Appendino, María Luz Bellido Cabello De Alba
Abstract: Disclosed are fluorescent compounds useful as intracellular pH probes. In particular, the invention teaches a two-photon absorbing, water soluble, fluorescent compound, a fluorene derivative, which is effective as a near-neutral pH indicator and particularly as an intracellular probe. A method for chemical synthesis of the claimed compounds is provided.
Type:
Grant
Filed:
July 11, 2012
Date of Patent:
June 24, 2014
Assignee:
University of Central Florida Research Foundation, Inc.
Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
Abstract: Compositions and methods for treating post angioplasty restenosis, arteriosclerosis, and/or smooth muscle cell proliferation and/or neointimal hyperplasia in vascular tissues, and at least one composition of a redox based curcumin derivative, DAP-F(p) and a pharmaceutically acceptable carrier, are described.
Abstract: Compounds of the hydroxytolan family kill tumor cells, inhibit tumor growth and development, and are thus useful in method for treating a tumor or cancer in subjects in need thereof. These compounds are also active in preventing or treating a variety of skin diseases and conditions. The most preferred hydroxytolan compounds are 4,4?-dihydroxytolan. (KST-201), 4 hydroxy 4? trifluoromethyltolan or 4? hydroxy 4 trifluoromethyltolan (KST-213), 3,4?,5-trihydroxytolan or 3?,4,5?-trihydroxytolan (KST-301) and 3,3?,5,5?-tetrahydroxytolan (KST-401). The compounds and methods of using them alone and in combination with ascorbate and certain cyclic compounds to inhibit the development, growth or metastasis of tumor/cancer or preneoplastic cells, or to prevent or treat skin disorders in a subject are disclosed.
Abstract: The present invention relates to a therapeutic agent for neuropathic pain containing, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof: (wherein R1, R2, R3, R4, R5, R6, R7, R8, A, and B have the same definitions as those described in the specification), and an animal model produced by administering (+)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octohydro-trans-quinolino[2,3-g]isoquinoline. The present invention makes it possible to perform drug treatment for neuropathic pain. The therapeutic effect of a compound against neuropathic pain can also be evaluated.
Abstract: The present invention relates to “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
Type:
Grant
Filed:
April 2, 2012
Date of Patent:
December 17, 2013
Assignee:
Acetylon Pharmaceuticals
Inventors:
John H. Van Duzer, Ralph Mazitschek, Walter Ogier, James E. Bradner, Guoxiang Huang, Dejian Xie, Nan Yu
Abstract: The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
December 10, 2013
Assignee:
Amicus Therapeutics, Inc.
Inventors:
Robert Boyd, Gary Lee, Philip Rybczynski
Abstract: The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a ryanodine antagonist, e.g. dantrolene, to inhibit or prevent nerve cell injury or death.
Abstract: Disclosed is the use of an aqueous dispersion comprising (a) a micronized sparingly soluble organic benzophenone derivative of formula (1), selected from the crystal modifications (B) and (C), wherein the crystal modification (B) is characterized by a peak in the X-ray diffraction pattern at a d-spacing of about 7.70; and wherein the crystal modification (C) is characterized by a peak in the X-ray diffraction pattern at a d-spacing of about 7.06; and (b) a dispersing agent selected from anionic, non-ionic and amphoteric surfactants; for protecting the human skin from browning and skin aging. The new crystal modification (C) represents a thermodynamically stable compound of formula (1) at 25° C. This modification is therefore suitable in dispersions comprising micro-fine particles.
Type:
Grant
Filed:
April 28, 2008
Date of Patent:
October 15, 2013
Assignee:
BASF SE
Inventors:
Martin Vogt, Stefan Müller, Julie Grumelard, Cyrille Deshayes, Holger Paul, Jürg Haase, Thomas Ehlis
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Type:
Grant
Filed:
January 30, 2012
Date of Patent:
October 8, 2013
Assignee:
Bristol-Myers Squibb Company
Inventors:
John A. Bender, Omar D. Lopez, Gan Wang, Makonen Belema, John F. Kadow
Abstract: Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.